Related Experiment Video
Updated: Aug 6, 2026
05:35
Ovarian Cancer Patient-Derived Organoid Models for Pre-Clinical Drug Testing
Published on: September 15, 2023
Successful Delivery Following Ex Vivo Organoid Drug Testing for Unexplained Recurrent Pregnancy Loss
Lijun Huang1,2, Cheng Tan3, Pei Xu1
1Department of Obstetrics and Gynecology, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510150, China.
Maternal-Fetal Medicine (Wolters Kluwer Health, Inc.)
|July 22, 2026
Summary
Patient-derived organoids (PDOs) guided personalized therapy for unexplained recurrent pregnancy loss (URPL). This approach identified a triple-drug regimen, leading to a successful pregnancy and birth, demonstrating a new precision medicine paradigm for URPL.
Area of Science:
- Reproductive Medicine
- Organoid Technology
- Precision Medicine
Background:
- Unexplained recurrent pregnancy loss (URPL) presents a significant unmet clinical need.
- Current empiric treatments for URPL have limited efficacy.
- Personalized therapeutic discovery is crucial for managing URPL.
Purpose of the Study:
- To demonstrate the proof-of-concept for patient-derived organoids (PDOs) in guiding precision therapy for URPL.
- To leverage PDOs for personalized drug testing and therapeutic discovery in a patient with URPL.
Main Methods:
- Endometrial biopsies were used to culture patient-derived organoids (PDOs) and stromal cells.
- Organoid growth responses were assessed using RNA-sequencing and functional assays.
- A synergistic triple-therapy regimen was identified through PDO-based drug testing.
Main Results:
- Histological analysis revealed endometrial fibrosis and altered immune cell infiltration.
- PDOs showed delayed epithelial growth, indicating potential therapeutic targets.
- The identified triple-therapy (aspirin, low-dose heparin, almuabumab) resulted in an ongoing pregnancy.
- A healthy neonate was delivered via cesarean section at 34 weeks gestation.
Conclusions:
- Patient-derived organoids (PDOs) represent an innovative therapeutic model for URPL.
- This study establishes a precision medicine paradigm integrating organoid pharmacology with pregnancy surveillance.
- Findings highlight the potential of PDO-guided therapy for refractory URPL cases, warranting further investigation in larger cohorts.
